Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Releases Quarterly Earnings Results, Misses Expectations By $0.74 EPS

Calliditas Therapeutics AB (publ) (NASDAQ:CALTGet Free Report) released its earnings results on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74), Yahoo Finance reports. The business had revenue of $28.43 million during the quarter, compared to the consensus estimate of $35.78 million. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 133.08%.

Calliditas Therapeutics AB (publ) Price Performance

NASDAQ CALT opened at $22.42 on Friday. Calliditas Therapeutics AB has a twelve month low of $15.25 and a twelve month high of $29.30. The stock has a fifty day simple moving average of $20.60 and a 200 day simple moving average of $21.19. The company has a debt-to-equity ratio of 2.89, a quick ratio of 3.08 and a current ratio of 3.13.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reduced their price target on shares of Calliditas Therapeutics AB (publ) from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Friday.

Read Our Latest Stock Report on CALT

Calliditas Therapeutics AB (publ) Company Profile

(Get Free Report)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.

Recommended Stories

Earnings History for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with's FREE daily email newsletter.